Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
M&A activity
confidence 96%
filed 2026-07-15
Item 1.01
Senti Biosciences entered into an Agreement and Plan of Merger on July 14, 2026, whereby a newly formed company controlled by Celadon Partners will acquire substantially all of the company's Gene-Circuit-enabled pipeline assets (including SENTI-202) in exchange for a contingent value right with up to $60 million in milestone payments. The transaction constitutes a material change of control, with Celadon beneficially owning 54.6% to 77.5% of the company's common stock post-closing, and requires stockholder approval.
View raw filing on EDGAR →
6-K
M&A activity
confidence 99%
filed 2026-07-15
GSK announces completion of its acquisition of Nuvalent, Inc., a clinical-stage biopharmaceutical company, for approximately $10.6 billion in aggregate equity value (net $9.4 billion). The announcement explicitly states "GSK completes acquisition of Nuvalent, Inc." and describes the transaction as adding three lung cancer assets to GSK's oncology portfolio, including two assets with FDA Breakthrough Therapy designations and expected 2026 launches with "multi-blockbuster potential." This is a material acquisition completion disclosing a substantial change of control and strategic expansion.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-15
Item 1.01
International Stem Cell Corporation entered into a Membership Interest Purchase Agreement on July 10, 2026, to sell 100% of Lifeline Cell Technology, LLC to American Type Culture Collection, Inc. for $25.0 million. This is a material disposition of a subsidiary representing a significant asset sale, with customary closing conditions and stockholder approval requirements, clearly constituting a material M&A transaction under Item 1.01.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-14
Item 1.01
First Bancorp entered into a definitive Agreement and Plan of Merger and Reorganization to acquire First Carolina Bancshares Corporation in a stock-and-cash transaction valued at approximately $166 million, with consideration of 1,967,017 shares and $40 million in cash. The transaction was unanimously approved by both boards and is expected to close in late Q4 2026 or early Q1 2027, subject to customary closing conditions including shareholder and regulatory approvals, and will substantially expand First Bancorp's South Carolina presence and increase its deposit base by over 50%.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-14
Item 8.01
The filing discloses that Hawthorn Bancshares, Inc. (HBI) has received all required regulatory approvals as of July 10, 2026, to complete its acquisition of FSC Bancshares, Inc. (FBI) pursuant to an Agreement and Plan of Reorganization entered into on April 29, 2026. The transaction is expected to close in Q3 2026, pending FBI shareholder approval and customary closing conditions. This is a material acquisition event that would significantly affect a reasonable investor's assessment of HBI.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-07-14
Item 1.01
Willis Lease Finance Corporation's subsidiary entered into a definitive Purchase and Sale Agreement on July 10, 2026, to acquire a portfolio of 12 commercial aircraft and 13 spare aircraft engines for approximately $379.3 million, expanding the company's lease portfolio and customer base with closing expected in Q3 2026.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-14
Item 1.01
NextCure entered into a definitive merger agreement with Avere Therapeutics on July 14, 2026, whereby NextCure will acquire Avere in an all-stock transaction. The combined company will operate as Avere Therapeutics, with NextCure stockholders owning approximately 1.21% post-closing, accompanied by a concurrent $320 million private placement financing and expected to close in H2 2026.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-14
Item 7.01
The Company announced formation of a special committee of independent directors to evaluate strategic alternatives "which may include a possible transaction involving the Company." The retention of financial advisor Solomon Partners and legal advisor Willkie Farr & Gallagher LLP to assist with the strategic review process signals active consideration of M&A activity. While no transaction has been entered into yet, the initiation of a formal strategic review process evaluating potential acquisitions, mergers, or other transactions is a material disclosure that would affect a reasonable investor's assessment of the registrant's future direction.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-14
Item 8.01
The filing discloses a material milestone in a merger transaction: on July 13, 2026, the U.S. Department of Justice granted early termination of the Hart-Scott-Rodino Act waiting period for RE/MAX Holdings' proposed merger with The Real Brokerage Inc. This represents a significant regulatory clearance event in the completion of the contemplated transaction, removing a key closing condition. The merger agreement was entered into on April 26, 2026, and this disclosure documents progress toward consummation of the transaction.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-14
The 6-K discloses a material acquisition transaction: Real Brokerage Inc. entered into a Merger Agreement with RE/MAX Holdings on April 26, 2026, and on July 13, 2026, the U.S. Department of Justice granted early termination of the HSR Act waiting period, clearing a major regulatory hurdle toward completion. The filing provides detailed disclosure of the transaction structure, regulatory approvals obtained, and remaining closing conditions, consistent with Item 1.01 (Material Agreements) or Item 2.01 (Completion of Acquisition or Disposition) disclosure obligations.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-14
Item 7.01
This Item 7.01 disclosure concerns a proposed reverse merger transaction between VYNE Therapeutics and Yarrow Bioscience, expected to close approximately July 24, 2026. The filing references a Form S-4 registration statement (File No. 333-294804) containing a proxy statement/prospectus, and the presentation discusses the combined company's strategy, leadership, and clinical pipeline post-transaction. Although styled as a Regulation FD disclosure of an investor presentation, the substance is disclosure of material acquisition activity—specifically a reverse merger that constitutes a change of control.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-14
Item 1.01
Spero entered into an exclusive license agreement with Innovent Biologics on July 8, 2026, acquiring worldwide rights (excluding Greater China) to develop, manufacture, and commercialize SP001, a Phase 2-ready anti-CD40L monoclonal antibody. The transaction includes an upfront payment of $35 million, up to $1.05 billion in milestone payments, and tiered royalties, establishing the foundation of Spero's new immunology pipeline.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-14
EX-99.1
Thomson Reuters has signed a definitive agreement to enter into a joint venture with KKR, selling a 51% stake in its Global Print business for approximately $500 million in gross proceeds while retaining 49% equity interest. This constitutes a material disposition and change of control of a business segment, directly falling under Item 1.01/1.02 (M&A activity). The transaction is substantial, involves a major investment firm, and is expected to close in Q4 2026.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-14
Item 1.01
Diodes Incorporated entered into a definitive Agreement and Plan of Merger on July 10, 2026, to acquire Elevate Semiconductor, Inc. for a $250 million base purchase price plus up to $50 million in earnout payments. The all-cash transaction is expected to contribute approximately $50 million in revenue in the first twelve months post-close and be immediately accretive to revenue, gross margin, and earnings per share.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-07-14
Item 2.01
flyExclusive completed a material acquisition of Jet.AI's aviation assets on July 14, 2026, pursuant to Amendment No. 5 to the Amended and Restated Merger Agreement executed on July 13, 2026. The transaction involved a merger of Merger Sub into SpinCo (a Jet.AI entity), with SpinCo becoming a wholly owned subsidiary of flyExclusive, and consideration consisting of 7,096,117 shares of Company Common Stock, aircraft, customer relationships, future aircraft delivery positions, SPCX marketable securities, and cash.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-14
Item 2.01
On July 14, 2026, Ligand Pharmaceuticals completed its acquisition of XOMA Royalty Corporation, with stockholders receiving $39.00 per share in cash plus contingent value rights tied to pending litigation proceeds. The transaction constitutes a material change of control and merger completion, with the company's stock delisted from Nasdaq and registration to be terminated via Form 15.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-14
Item 1.01
Ligand Pharmaceuticals completed its acquisition of XOMA Royalty Corporation on July 14, 2026, for $39.00 per share in cash (approximately $739 million equity value) plus contingent value rights. The transaction doubles Ligand's royalty portfolio from approximately 100 to over 200 assets, adds seven commercial products and 14 late-stage development programs, and is expected to be accretive to earnings per share by $0.50 and $1.50 in 2026 and 2027 respectively.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-14
EX-99.1
Navigator Holdings announced the signing of definitive agreements to sell eight gas carriers and its shareholding in the Unigas Joint Venture for approximately $183 million to existing Unigas partners. This is a material disposition transaction involving the sale of significant fleet assets and a joint venture stake, expected to close by Q4 2026. The transaction represents a substantial capital event affecting the company's fleet composition and financial position.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-07-14
Item 1.01
Jaguar Health's subsidiary Napo entered into a new three-year manufacturing and supply agreement with Alivus on July 9, 2026, to continue supplying crofelemer for Mytesi®, the company's FDA-approved prescription drug product. This is a material definitive agreement that secures the supply chain for the company's primary commercial product and includes minimum purchase commitments with potential financial obligations. While this is a renewal rather than a new relationship, the binding three-year commitment with specified minimum quantities and financial penalties for shortfalls constitutes a material agreement affecting the company's operational and financial obligations.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-14
Item 2.01
Apollo-managed funds completed the acquisition of Emerald Holding, Inc. on July 14, 2026, for $5.03 per share in cash, resulting in a change of control and the cessation of Emerald's NYSE trading. The transaction also included the acquisition of Questex, LLC, creating a combined B2B experiential events and media platform, with Emerald becoming a wholly-owned subsidiary and its board members ceasing service.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-14
Item 2.01
Ares Real Estate funds completed an all-cash acquisition of Whitestone REIT for $19.00 per share, valued at approximately $1.7 billion, resulting in a change of control and the company's delisting from NYSE. The transaction included the merger of Whitestone with Merger Sub and the merger of Whitestone's operating partnership with Merger OP, with Whitestone ceasing to exist as a publicly traded entity.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-14
Item 1.01
Strategic Storage Trust VI, Inc. entered into a definitive Agreement and Plan of Merger on July 14, 2026, to acquire Strategic Storage Growth Trust III, Inc. in an all-stock transaction. The merger combines two SmartStop-sponsored REITs and includes acquisition of 12 wholly-owned self-storage facilities, 50% equity interests in three unconsolidated real estate ventures, and beneficial interests in three DST-sponsored programs, with a combined company expected to have a total asset value of approximately $1.2 billion.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-14
Item 1.01
Research Alliance Corp IV entered into multiple material definitive agreements in connection with its initial public offering, including an Underwriting Agreement, Investment Management Trust Agreement, Registration and Shareholder Rights Agreement, and Private Placement Shares Purchase Agreement. These agreements establish the company's capitalization and governance framework for pursuing a business combination.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-14
EX-99.1
The press release announces termination of a letter of intent for the acquisition of AI Financial Corporation's subsidiary Alt5 Sigma Canada, Inc. This is a material M&A event — the termination of a proposed transaction. The statement from Chief Strategy Officer Matthew Nicoletti explicitly states "Perpetuals has decided not to further pursue the acquisition" and "the earlier letter of intent has been terminated," which constitutes a material change in the status of a contemplated acquisition that would affect investor assessment of the company's strategic direction and capital allocation.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-14
Item 8.01
Churchill Capital Corp XI and Agility Robotics announced the confidential submission of a draft Form S-4 registration statement on July 13, 2026, in connection with their previously disclosed Merger Agreement. The filing discloses a material acquisition/business combination transaction expected to close in 2026, with approximately $620 million in gross proceeds, creating a publicly listed pure-play humanoid robotics company. This is a clear entry into a material merger and change of control transaction requiring shareholder approval.
View raw filing on EDGAR →
6-K
M&A activity
confidence 85%
filed 2026-07-14
EX-99.1
Youxin Technology announced a non-binding term sheet to make a strategic investment of US$20 million in RiverBit Holding Limited to acquire a 10% equity interest upon achievement of operating milestones (2,000 daily users and US$100 million daily trading volume within three months of launch). Although non-binding and contingent on due diligence and definitive agreements, this represents a material acquisition of a minority equity interest in a third party, which falls within the scope of M&A activity disclosures. The investment amount and strategic nature would affect a reasonable investor's assessment of the company's capital allocation and business strategy.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-14
Item 8.01
This Item 8.01 discloses a supplement to the definitive proxy statement for a merger transaction. The core event is the pending merger between Avanos and A-AV Holdco I, Inc., with stockholder approval scheduled for July 22, 2026. Although the filing addresses litigation and supplemental disclosures, the material event is the merger activity itself—a change of control transaction that was previously disclosed on April 13, 2026, and is now being supplemented in response to stockholder litigation and demand letters. The supplement updates key merger-related disclosures including financial forecasts, valuation analyses, and conflict-of-interest information, all central to the merger transaction.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-14
AstraZeneca has entered into an exclusive global license agreement with Dizal Pharmaceutical to acquire worldwide rights to develop and commercialize Zegfrovy (sunvozertinib), a novel EGFR inhibitor for lung cancer. The transaction involves an upfront payment of $600 million plus up to $900 million in milestone payments, representing a material acquisition of intellectual property and commercial rights that would affect a reasonable investor's assessment of the company's oncology portfolio and capital allocation.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-14
Item 2.01
Catalyst Bancorp completed its acquisition of Lakeside Bancshares and Lakeside Bank effective July 14, 2026, for $41.1 million in cash ($19.58 per share). The transaction materially expanded Catalyst's asset base from $288.5 million to approximately $620 million and added four branch locations in Southwest Louisiana.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-07-14
Item 1.01
The Sponsor has entered into two material definitive agreements—a Digital Asset Trading Agreement with StoneX Digital LLC and a Liquidity Provider Agreement with Virtu Financial Singapore Pte. Ltd.—to establish crypto asset trading counterparties for the Fund. These agreements establish ongoing principal-to-principal trading relationships for spot transactions in 17 eligible crypto assets and are disclosed under Item 1.01 (Entry into a Material Definitive Agreement), the standard Item for material contract entry. While not a traditional M&A transaction, the entry into these material trading agreements constitutes a material operational and financial commitment that would affect investor assessment of the Fund's trading infrastructure and counterparty relationships.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-13
EX-99.1
Diana Shipping Inc. announces an extension of its tender offer to acquire all outstanding shares of Genco Shipping & Trading Limited not already owned by Diana. The offer, valued at $27.34 per share ($24.80 cash plus one Diana share), represents a material acquisition activity. As of July 10, 2026, 11.1 million shares (29.7% of outstanding shares not owned by Diana) have been tendered. This is a direct M&A transaction with committed financing of $1.412 billion, representing a 53% premium to Genco's undisturbed share price, and would constitute a change of control if completed.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-13
Item 7.01
TriCo Bancshares announced execution of a definitive Agreement and Plan of Reorganization and Merger with First Hawaiian, Inc., whereby First Hawaiian will acquire TriCo in an all-stock transaction at 2.095 FHI shares per TCBK share ($63.12 per share). The transaction creates a combined entity with ~$34 billion in assets and is expected to close by end of 2026, subject to regulatory and shareholder approvals. This is a material acquisition/change of control event requiring disclosure under Item 1.01 or 2.01, disclosed here via Item 7.01 (Regulation FD Disclosure).
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-13
Item 8.01
First Hawaiian, Inc. executed a definitive Agreement and Plan of Reorganization and Merger to acquire TriCo Bancshares in an all-stock transaction at 2.095 FHB shares per TCBK share ($63.12 per share), creating a combined entity with approximately $34 billion in assets and making it the 6th largest bank headquartered in the Western U.S., with closing expected by end of 2026.
View raw filing on EDGAR →
8-K
M&A activity
confidence 94%
filed 2026-07-13
Item 1.01
Plug Power entered into two material asset disposition transactions: (1) a definitive agreement to sell the Graham, Texas Project to Stream US Data Centers for up to $76.5 million (base $50 million plus up to $26.5 million earnout) with expected closing July 31, 2026, and (2) an amended purchase and sale agreement for the New York Gateway Project with a fixed purchase price of $142 million and staged closing structure extending to March 31, 2027. These dispositions are expected to deliver over $80 million in near-term liquidity as part of a broader $275 million strategic infrastructure optimization initiative.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-07-13
Item 2.01
Edgewise completed the sale of its sevasemten compound and muscular dystrophy program to Servier Pharmaceuticals for $1.55 billion in upfront cash plus up to $1.1 billion in milestone payments (total consideration up to $2.65 billion), completed on July 10, 2026. This material disposition fundamentally reshapes the company's strategic focus toward cardiovascular programs.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-13
Item 2.01
Esperion Therapeutics completed its acquisition by Parent on July 13, 2026, with shareholders receiving $3.16 per share in cash plus contingent value rights (CVRs) with up to $100 million in additional contingent payments, totaling approximately $1.1 billion in aggregate consideration. The transaction resulted in Esperion becoming a wholly owned subsidiary of Parent, with the company's board replaced by Parent's designees and the company's certificate of incorporation and bylaws amended in connection with the merger consummation.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-13
Item 2.01
FSP completed the sale of two office buildings (6550 and 6560 Greenwood Plaza Boulevard, Englewood, Colorado) totaling approximately 196,236 square feet to University of Colorado Health for $19,356,000 on July 8, 2026, pursuant to a Purchase and Sale Agreement dated May 26, 2026. This is a material disposition of real estate assets, with proceeds used to repay approximately $8.5 million in debt. The transaction is disclosed under Item 2.01 (Completion of Acquisition or Disposition of Assets) and includes pro forma financial statements showing the impact on the registrant's balance sheet and operations.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-07-13
EX-99.1
This exhibit is an Information Statement disclosing a proposed business combination — the merger of ITA (Inversiones y Técnicas Aeroportuarias) into ASUR to internalize technical assistance and technology transfer services. The transaction involves a capital increase of approximately 7.25 million shares (from 300 million to 307.25 million outstanding shares) to be issued to ITA's shareholders. The document explicitly describes this as an "Integration" and "Business Combination" requiring shareholder approval at an Extraordinary General Shareholders' Meeting on August 20, 2026. This is a material acquisition/merger activity under Item 1.01 or 2.01 equivalent for a foreign private issuer.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-07-13
Item 7.01
Williams announced a $5.34 billion joint venture financing agreement with Blackstone, Apollo, and KKR to support five Power Innovation projects. Under the terms, the partners receive a 49% noncontrolling equity interest in exchange for $5.34 billion in committed capital, while Williams retains 51% interest and operational control. This represents a material capital transaction and partial disposition of equity interests in the Power Innovation projects, which constitutes M&A activity under Item 1.01/2.01 framework, though structured as a joint venture financing rather than a traditional acquisition.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-07-13
Item 7.01
The disclosure centers on the pending separation of ADI Global Distribution Inc. from Resideo Technologies, Inc., with completion expected August 3, 2026, and ADI trading to commence August 4, 2026. This constitutes a material change of control and restructuring event. While Item 7.01 is used for the investor day announcement, the substance is a major M&A activity—the spin-off of a significant business segment—which materially affects the registrant's structure and shareholder value.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-13
Item 8.01
This Item 8.01 discloses pro forma financial statements reflecting the impact of an Asset Purchase Agreement entered into on April 7, 2026, between Plum III Merger Corp., Sierra Blanca Quarry LLC, and Tactical Resources Corp. The filing explicitly references "the previously announced business combination among Plum, Tactical and PubCo" and presents unaudited pro forma balance sheet and income statement as of April 30, 2026 to illustrate the transaction's financial impact. This constitutes material M&A activity—specifically a business combination/merger transaction—even though the pro forma statements are furnished for illustrative purposes only and the transaction had not yet closed as of the filing date.
View raw filing on EDGAR →
6-K
M&A activity
confidence 98%
filed 2026-07-13
EX-99.1
Greenfire Resources entered into a definitive agreement to acquire all issued and outstanding shares of Connacher Oil and Gas Limited for approximately C$1.277 billion in cash, with closing expected in August 2026. The acquisition is expected to increase pro forma production from ~14,500 to ~34,000 Bbl/d and generate identified synergies of ~$30 million annually.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-07-13
Item 1.01
The Sponsor deposited $229,700 into the trust account and entered into a convertible promissory note (Second Extension Note) to extend the Company's deadline to consummate a Business Combination from June 22 to July 22, 2026, directly affecting the SPAC's ability to complete its material acquisition.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-13
Item 7.01
Tavia Acquisition Corp. and Vita Inclinata Technologies announced entry into a non-binding letter of intent for a proposed business combination (de-SPAC transaction) that would result in Vita becoming publicly traded. The transaction values Vita at a pre-money enterprise value of $450 million. Although the LOI is non-binding and subject to definitive agreement execution, this represents a material M&A activity disclosure under Item 1.01 principles—the announcement of a proposed merger or business combination that would materially affect the registrant.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-07-13
Item 1.01
Launch One Acquisition Corp. entered into Non-Redemption Agreements with shareholders to extend its Business Combination Period from July 15, 2026 to January 15, 2027, securing shareholder support and trust account funds necessary for pursuing a future business combination.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-13
The filing discloses a material acquisition: SoundHound AI's merger with LivePerson, Inc., pursuant to an Amended and Restated Merger Agreement dated July 2, 2026. The 8-K provides unaudited pro forma condensed combined financial information showing the combined entity's balance sheet and statements of operations, reflecting total consideration of approximately $304 million in stock and cash. This is a material change of control transaction that would significantly affect investor assessment of the registrant.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-13
Item 8.01
The filing discloses termination of a non-binding letter of intent for a proposed business combination whereby SC II Acquisition Corp. would acquire 100% of a payments technology company's equity. The termination of a material acquisition transaction, even at the LOI stage, is a significant M&A event that would affect investor assessment of the SPAC's strategic direction and prospects. The company explicitly states it "does not intend to pursue the Proposed Transaction" as of July 12, 2026.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-13
Item 8.01
TransDigm announced withdrawal from its proposed acquisition of Stellant Systems, Inc. from Arlington Capital Partners on July 13, 2026. The filing explicitly states the Company "elected to withdraw from its proposed acquisition" and that the Seller subsequently provided notice of termination. This is a material M&A event—the termination of a proposed acquisition—that would affect a reasonable investor's assessment of the Company's capital allocation strategy and near-term growth prospects.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-13
The filing discloses entry into a definitive Business Combination Agreement on July 10, 2026, whereby Matinas BioPharma will merge with GH Power Inc. through a plan of arrangement, with GHP International becoming the public parent company. This is a material acquisition/change of control transaction expected to close in Q4 2026. The filing also discloses a concurrent definitive stock purchase agreement to divest Matinas BioPharma Nanotechnologies, Inc. (including MAT2203 and LNC platform) to Azurity Pharmaceuticals for $4.0 million upfront plus up to $17.5 million in milestones and royalties. Both transactions are disclosed under Item 1.01 (Entry into a Material Definitive Agreement) and constitute material M&A activity.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-13
The filing discloses WRAP's entry into a material definitive agreement (Item 1.01) to acquire 74,918 Series A Preferred Shares of Frenel Imaging Ltd. for $2,000,000, with an exclusive distribution license agreement for Frenel's proprietary thermal-polarimetric imaging technology in the U.S. and NATO markets. This represents a strategic investment and material acquisition of equity and exclusive commercialization rights that would affect a reasonable investor's assessment of the company's strategic direction and financial position.
View raw filing on EDGAR →